NuCana BioMed Ltd. raised £6.74 million (US$10.5 million) in a Series A round to advance a series of modified nucleoside analogues in cancer indications and has set its sights on becoming the Inhibitex Inc. or even the Pharmasset Inc. of the cancer world. Read More

LONDON – Galapagos NV reported strong efficacy data from a Phase IIa proof-of-concept study of its selective Janus kinase 1 (JAK 1) inhibitor GLP0634 in rheumatoid arthritis and said it is now in partnering discussions. Read More

LONDON – The mechanism of action of paracetamol has been unveiled, leaving the way clear for the development of new analgesics that are more effective and safer than paracetamol itself. Read More

Immunicum AB is finalizing the first closing of an SEK25 million (US$3.6 million) financing round to take forward a series of therapeutic vaccine technologies for treating cancer. Read More

LONDON – The first patients have been enrolled in a ₤5.5 million (US$8.5 million) project that aims to provide the foundation stone of a single nationwide system for tumor gene testing to enable rapid adoption of targeted cancer drugs. Read More

Elan Corp. plc is entering a $10 million alliance with the University of Cambridge that will focus on the discovery of drugs that modulate protein misfolding processes associated with neurodegenerative conditions, such as Alzheimer's disease and Parkinson's disease. Read More

• BioLineRx Ltd., of Jerusalem, said it received approval from Indian regulators to start the Phase II/III CLARITY trial of BL-1020, an oral GABA-enhanced antipsychotic for treating schizophrenia. Overall, the study is expected to be conducted at about 18 sites in India, 14 sites in Romania and four sites in Israel. Read More